Endophthalmitis Cultures (PROSPER)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by Vanderbilt University.
Recruitment status was Recruiting
Information provided by (Responsible Party):
Stephen J. Kim, MD, Vanderbilt University
First received: December 19, 2011
Last updated: NA
Last verified: July 2011
History: No changes posted
The intent of this surveillance study will be to obtain written permission from patients with bacterial endophthalmitis in order to compare sterilization rates of their cultured bacterial isolates to standard therapy (vancomycin and ceftazidime) versus combination therapy with vancomycin, ceftazidime, and moxifloxacin.
- Cultured bacterial isolates will demonstrate faster in vitro sterilization rates with combination treatment (vancomycin, ceftazidime, and moxifloxacin) compared to "standard therapy" with vancomycin and ceftazidime.
- Longitudinal analysis of resistance patterns of cultured isolates will show increasing rates of multi-antibiotic resistance.
||Observational Model: Case-Only
Time Perspective: Prospective
||Prospective Surveillance of Patients With Endophthalmitis for Multi-antibiotic Resistance (PROSPER) Study
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
Adult patients over 18 years of age presenting with endophthalmitis and able to sign consent.
|Ages Eligible for Study:
||18 Years and older (Adult, Senior)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Vanderbilt Eye Institute
- all adult patients age 18 or greater presenting with bacterial endophthalmitis to the Vanderbilt Eye Institute and who grow positive cultures
- Patients < 18 years of age or those patients without positive cultures
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01496794
|Vanderbilt Eye Institute
|Nashville, Tennessee, United States, 37232 |
|Contact: Stephen J Kim, MD 615-936-2020 firstname.lastname@example.org |
|Principal Investigator: Stephen J Kim, MD |
||Stephen J Kim, MD
||Stephen J. Kim, MD, Assistant Professor of Ophthalmology, Vanderbilt University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 19, 2011
||December 19, 2011
||United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 23, 2016